VRTX · News · 20260901N

Crinetics Acquisition Financing

VERTEX PHARMACEUTICALS INC / MA · 2026-09-01 · Importance 75 · Surprise 60 · In source text

Vertex completed its acquisition of Crinetics Pharmaceuticals on September 1, 2026, for approximately $10.0 billion in equity value. The transaction adds PALSONIFY and atumelnant and establishes rare endocrine diseases as a new growth pillar. The two therapies are projected to generate more than $5 billion in combined annual peak revenue. Vertex expects the transaction to become accretive to non-GAAP operating income by 2029, while expanding its executive leadership team to support the enlarged portfolio.

Key facts

• VERTEX PHARMACEUTICALS INC / MA acquired Crinetics Pharmaceuticals for an equity value of approximately $10.0 billion. source
• VERTEX PHARMACEUTICALS INC / MA completed its $10 billion acquisition of Crinetics Pharmaceuticals (described as $10 billion in Yahoo Finance coverage). source
• VERTEX PHARMACEUTICALS INC / MA expects PALSONIFY and atumelnant to generate over $5 billion in combined annual revenue. source
• VERTEX PHARMACEUTICALS INC / MA anticipates the Crinetics transaction to become accretive to non-GAAP operating income by 2029. source
• VERTEX PHARMACEUTICALS INC / MA added PALSONIFY and atumelnant to its innovation pipeline through the Crinetics acquisition. source
• VERTEX PHARMACEUTICALS INC / MA announced Charles Wagner is taking an expanded COO role as part of an expanded executive leadership team. source
• VERTEX PHARMACEUTICALS INC / MA announced Jonathan Poole is becoming the new CFO. source
• VERTEX PHARMACEUTICALS INC / MA announced Jasper van Grunsven is joining as EVP, Chief Pain and New Product Planning Officer. source

Impact estimates